Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Treasury Shares (2016 - 2025)

Lineage Cell Therapeutics' Treasury Shares history spans 6 years, with the latest figure at $2.9 million for Q4 2016.

  • For Q4 2016, Treasury Shares fell 83.97% year-over-year to $2.9 million; the TTM value through Dec 2016 reached $2.9 million, down 83.97%, while the annual FY2016 figure was $2.9 million, 83.97% down from the prior year.
  • Treasury Shares reached $315000.0 in Q4 2025 per LCTX's latest filing, down from $334000.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $939000.0 in Q4 2022 to a low of $315000.0 in Q4 2025.
  • Average Treasury Shares over 4 years is $517000.0, with a median of $501000.0 recorded in 2024.
  • Peak YoY movement for Treasury Shares: surged 413.81% in 2013, then plummeted 85.47% in 2016.
  • A 5-year view of Treasury Shares shows it stood at $8.4 million in 2012, then soared by 413.81% to $43.0 million in 2013, then plummeted by 53.78% to $19.9 million in 2014, then fell by 9.34% to $18.0 million in 2015, then crashed by 83.97% to $2.9 million in 2016.
  • Per Business Quant, the three most recent readings for LCTX's Treasury Shares are $2.9 million (Q4 2016), $2.9 million (Q3 2016), and $2.9 million (Q2 2016).